Koya Medical (“Koya”), a medical technology company advancing evidence-based therapies for vascular disease, has announced its participation in the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3, 2024 at 4:50 pm ET.
Koya CEO, Andy Doraiswamy, PhD, will share updates on the company’s progress, including Dayspring, its novel integrative compression treatment for chronic edema in venous and lymphatic disorders, and its pipeline for addressing superficial and deep vein diseases.
Koya recently expanded its clinical evidence with the publication of its latest randomized multicenter trial, TEAYS, in the Journal of Vascular Surgery. Dayspring met both primary and secondary endpoints and showed a broad range of superior clinical benefits for patients using Dayspring compared to standard of care.
About Venous Disease and Lymphedema
An estimated 20 million Americans live with lymphedema, a progressive, incurable condition where a buildup of protein-rich fluid causes painful swelling in the arm, leg, and/or other regions of the body. For most, lymphedema requires lifelong maintenance and various levels of therapy to control swelling and pain. Lymphedema can result from a variety of factors, including chronic venous disease, cancer, infection, and surgery.
About Koya Medical
Founded in 2018 and headquartered in Dallas, Koya Medical is a medical technology company developing a portfolio of evidence-based treatments designed to improve clinical outcomes and patient experience in vascular disease.
LinkedIn at www.linkedin.com/company/koyamedical/
